CStone Pharmaceuticals (CSPHF)
| Market Cap | 1.08B -25.9% |
| Revenue (ttm) | 62.60M +110.0% |
| Net Income | -61.70M |
| EPS | -0.04 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 49.56 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,000 |
| Open | 0.71985 |
| Previous Close | n/a |
| Day's Range | 0.71985 - 0.71985 |
| 52-Week Range | 0.5945 - 1.0100 |
| Beta | 0.29 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 27, 2026 |
About CStone Pharmaceuticals
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor... [Read more]
Financial Performance
In 2025, CStone Pharmaceuticals's revenue was 269.58 million, a decrease of -33.80% compared to the previous year's 407.21 million. Losses were -437.00 million, 379.1% more than in 2024.
Financial numbers in CNY Financial StatementsNews
CStone Pharmaceuticals Earnings release: H1 2026
CStone Pharmaceuticals released its H1 2026 earnings on August 27, 2026, summarizing the period's financial results.
CStone Pharmaceuticals Slides: H1 2026
CStone Pharmaceuticals has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 27, 2026.
CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugem...
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an object...
CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
SUZHOU, China, April 19, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for onc...
CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
Rapid Advancement Across Core R&D Pipeline The global, multicenter Phase I/II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) is actively enrolling patients in Australia and China, an...
CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
Key Highlights: Excellent Safety Profile: As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approxi...
CStone Pharmaceuticals Earnings release: H2 2025
CStone Pharmaceuticals released its H2 2025 earnings on March 25, 2026, summarizing the period's financial results.
CStone Pharmaceuticals Slides: H2 2025
CStone Pharmaceuticals has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 25, 2026.
CStone Pharmaceuticals Annual report: H2 2025
CStone Pharmaceuticals has published its H2 2025 annual report on March 25, 2026.
CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small ce...